Receive our newsletter – data, insights and analysis delivered to you
July 29, 2009

Inovio Flu Vaccine Scores 100% in Animal Trials

Biomedical company Inovio has announced that its SynCon H1N1 influenza DNA vaccine has achieved 100% protection against swine origin influenza A/H1N1 viruses in animal studies. In the second study for the vaccine, mice immunised with A/H1N1 vaccine components recovered from virus infecti

By cms admin

Biomedical company Inovio has announced that its SynCon H1N1 influenza DNA vaccine has achieved 100% protection against swine origin influenza A/H1N1 viruses in animal studies.

In the second study for the vaccine, mice immunised with A/H1N1 vaccine components recovered from virus infection-induced morbidity significantly faster than the non-immunised control animals.

In a previous study, the Inovio team demonstrated that mice immunised with the SynCon H1N1 DNA vaccine provided 100% protection in a lethal challenge study against H1N1 virus.

Inovio CEO Joseph Kim said that the latest data further underscores the potential of the SynCon technology to create vaccines capable of protecting against emerging pandemic influenza viruses.

“Our SynCon influenza vaccines were developed prior to the emergence of the current swine flu strains and have yielded strong protective responses in animal models against a variety of unmatched influenza strains,” Kim said.

Inovio is one of the first pharmaceutical companies to report on the successful protection of vaccinated animals against the 2009 influenza A/H1N1 virus, as well as the first to report on preclinical results using pigs, a more natural host for the virus.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The company had previously reported data from an ongoing study in a pig model, in which the SynCon-based H1N1 vaccines achieved haemagglutination inhibition titers above the protection threshold in 100% of the vaccinated animals against the swine influenza virus.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU